Clinigen buys U.S. rights to Novartis' cancer drug Proleukin

British pharmaceutical firm Clinigen Group Plc said on Wednesday it acquired the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total of $210 million, including some future payments.

from Reuters: Health https://reut.rs/2E9Timn
via IFTTT

• Tweet
• Share
• Share
• Share
• Share